Kt Corporation ADR Stock
Your prediction
Pros and Cons of Kt Corporation ADR in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Kt Corporation ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | 2.500% | 5.128% | 7.895% | -4.651% | 3.797% | 46.429% | 29.134% |
| Freenet AG | -0.920% | -1.572% | -0.335% | -15.663% | -19.322% | 8.775% | 18.290% |
| Philippine Long Distance Telephone Company ADR | -0.590% | 0.599% | 3.067% | -13.402% | -6.667% | -19.231% | -16.832% |
| Telekom Austria AG | 1.380% | 2.191% | 2.191% | 8.457% | 14.254% | 52.226% | 35.714% |
News
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch